Kaliumchloride (Potassium Chloride)

• Kaliumchloride, an electrolyte replacement administered intravenously, is used to correct potassium deficits.
• Hypokalemia: restores normal serum potassium levels, reducing muscle weakness and cardiac disturbances.
• Potassium depletion: replenishes intracellular and extracellular potassium stores during acute loss.
• Prevention of cardiac arrhythmias due to low potassium: maintains cardiac electrical stability in at‑risk patients.
• Acute care settings: provides rapid potassium repletion during surgery, trauma or intensive‑care management.

• Potassium chloride dissociates in plasma to release potassium ions (K+). The increased extracellular potassium concentration drives passive diffusion into cells via the Na+/K+‑ATPase pump, restoring the normal transmembrane gradient. By raising serum potassium, the drug corrects the electrophysiological disturbances that underlie hypokalemia, stabilizing cardiac myocyte repolarization and skeletal muscle excitability. The effect is rapid, allowing clinicians to achieve target serum levels within minutes after intravenous administration.

Potassium chloride administered intravenously may be associated with a range of adverse reactions.

Common Side Effects

• Injection site pain: mild discomfort or burning at the infusion site.
• Hyperkalemia: transient elevation of serum potassium if administered too rapidly.
• Nausea or vomiting: gastrointestinal upset occurring shortly after infusion.
• Metallic taste: transient taste disturbance during infusion.

Serious or Rare Side Effects

• Cardiac arrhythmia: life‑threatening rhythm disturbances due to rapid potassium rise.
• Anaphylaxis: rare severe allergic reaction with hypotension, bronchospasm, or urticaria.
• Phlebitis: inflammation of the vein at the infusion site.

When using Kaliumchloride, clinicians should observe several safety measures to minimize risk.

• Renal function assessment: evaluate kidney function before and during therapy to avoid potassium accumulation.
• Serum potassium monitoring: check levels frequently to maintain target range and prevent hyperkalemia.
• Infusion rate control: administer over recommended time to reduce risk of cardiac events.
• Concomitant drug review: avoid simultaneous use with other potassium‑containing products or ACE inhibitors without monitoring.
• Contraindications: do not use in patients with severe hyperkalemia or untreated digitalis toxicity.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light, and retain in original packaging.

Potassium chloride can interact with several medicines, altering potassium balance or cardiac effects.

Major Interactions (Avoid)

• ACE inhibitors or ARBs: may cause additive hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): increase risk of dangerous potassium excess.
• Digoxin: heightened risk of digoxin toxicity when serum potassium is high.

Moderate Interactions (Monitor Closely)

• Non‑potassium‑containing diuretics: may require dose adjustments of potassium chloride.
• NSAIDs: can reduce renal potassium excretion, necessitating closer monitoring.
• Beta‑blockers: may mask symptoms of hyperkalemia, requiring vigilant serum checks.